Thelin
Generic name: sitaxsentan
Treatment for: Pulmonary Arterial Hypertension (PAH)
Encysive Pharmaceuticals Submits Complete Response to FDA for Thelin New Drug Application
HOUSTON, May 25, 2006 -- Encysive Pharmaceuticals today announced the submission of a complete response to the concerns and observations as noted in the March 24 approvable letter issued by the U.S. Food and Drug Administration (FDA) regarding the Company's New Drug Application (NDA) for Thelin (sitaxsentan sodium) 100 mg. The FDA is currently evaluating Thelin as a potential new oral treatment for pulmonary arterial hypertension.
"Encysive and the FDA have come to the mutual agreement that the Company's approach to responding to the items outlined in the approvable letter with our existing data set is reasonable, making possible the submission of a complete response," said Bruce D. Given, M.D., President and Chief Executive Officer of Encysive Pharmaceuticals. "We look forward to continuing our productive relationship with the Agency."
The Company expects to hear within 30 days whether the FDA accepts the submission for review.
Posted: May 2006
Related articles
- Encysive Pharmaceuticals Receives Written Response From FDA On Its Request for Formal Dispute Resolution for Thelin (Sitaxsentan Sodium) - September 6, 2007
- Encysive Pharmaceuticals Files Request for Formal Dispute Resolution With U.S. FDA to Contest Third Approvable Letter for Thelin - August 7, 2007
- Encysive Pharmaceuticals Provides Update for Thelin (Sitaxsentan Sodium) - July 13, 2007
- FDA Issues Third Approvable Letter for Thelin (Sitaxsentan Sodium) - June 18, 2007
- FDA Accepts Encysive’s Complete Response to Thelin New Drug Application - December 28, 2006
- Encysive Pharmaceuticals Submits Response to FDA For Thelin New Drug Application - December 15, 2006
- Encysive Expects to Submit Revised Response to Thelin Approvable Letter Within Several Days - December 14, 2006
- Encysive Submits Complete Response to FDA For Thelin New Drug Application - November 2, 2006
- FDA Issues Approvable Letter for Thelin; One Outstanding Item Remains - July 24, 2006
- FDA Grants Class 1 Review to Encysive Pharmaceuticals’ Complete Response to Thelin NDA - June 15, 2006
- Encysive Pharmaceuticals Receives Approvable Letter From FDA for Thelin - March 24, 2006
- Encysive Announces PDUFA Date for Thelin New Drug Application in Pulmonary Arterial Hypertension - July 14, 2005
- Encysive Pharmaceuticals Submits New Drug Application for Thelin - May 25, 2005
Thelin (sitaxsentan) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
